Synonyms: CD272, B and T lymphocyte attenuator
Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD.
|
|---|
| Molecular Weight | 145.5 kDa |
|---|---|
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05781451 | WITHDRAWN | Drug: LY3361237 | Primary Sjogren's Syndrome | Stanford University | 2025-01-01 | PHASE2 |
| NCT05789069 | ACTIVE_NOT_RECRUITING | Drug: HFB200603|Drug: Tislelizumab | Renal Cell Carcinoma; Melanoma; Non Small Cell Lung Cancer; Gastric Cancer; Colorectal Cancer | HiFiBiO Therapeutics | 2023-05-09 | PHASE1 |
| NCT05664971 | COMPLETED | Drug: Docetaxel|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carbo | Advanced Lung Cancer | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-09 | PHASE1; PHASE2 |
| NCT05000684 | COMPLETED | Drug: JS004 in combination with toripalimab | Advanced Lung Cancer | Shanghai Junshi Bioscience Co., Ltd. | 2021-08-27 | PHASE1; PHASE2 |
| NCT04477772 | COMPLETED | Recurrent/Refractory Malignant Lymphoma | Shanghai Junshi Bioscience Co., Ltd. | 2020-07-17 | PHASE1 | |
| NCT05427396 | TERMINATED | Drug: JS004|Drug: Toripalimab Injection | Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer | Shanghai Junshi Bioscience Co., Ltd. | 2022-07-28 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2024-04-17)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.